CAMBRIDGE, Mass. & SHANGHAI – Detailed results from the Phase III AENEAS trial showed that treatment with aumolertinib resulted in a clinically significant improvement in progression-free survival (PFS) as compared to gefitinib in first-line treatment of patients with Stage IIIB or IV non-small cell lung cancer (NSCLC) with the most...
Latest News
CAMBRIDGE, Mass. – Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the appointment of Sapna Srivastava, Ph.D., to its Board of Directors. “Sapna is a recognized leader in the biopharmaceutical industry with over two decades of...
VICTORIA, British Columbia & ROCKVILLE, Md. – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) announced today that the Company’s licensing partner, Otsuka Pharmaceutical Europe Ltd. (OPEL), filed an initial Marketing Authorization Application (MAA) for voclosporin for the treatment of lupus nephritis (LN) to the European Medicines Agency (EMA)....
ROCKVILLE, Md. & EDMONTON, Alberta — Aurinia Pharmaceuticals Inc. announced today the submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for AUR200, a potential next generation therapy for B-cell mediated autoimmune diseases. Upon receiving FDA clearance to proceed with proposed research, Aurinia...
Hamilton, Bermuda – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the publication of positive results from an in vivo study demonstrating significant inhibition of tumor growth by siRNA knock-down...
Australian and New Zealand researchers have accelerated research into Multiple Sclerosis by discovering two new locations of genes which will help to unravel the causes of MS and other autoimmune disease. Their findings will be published today in the prestigious journal Nature Genetics. “For decades the cause of MS has...
Canberra, Australia – Researchers from The Australian National University (ANU) have discovered a previously unknown ability of a group of immune system cells, known as Atypical B cells (ABCs), to fight infectious diseases such as malaria. The discovery provides new insight into how the immune system fights infections and brings...
DENVER, Colorado – Based on results from the CheckMate743 trial, the dual regimen of ipilimumab and nivolumab is the standard of care for the treatment of unresectable pleural mesothelioma. But research published today in the Journal of Thoracic Oncology (JTO) showed that a group of Australian patients treated with that...
Dublin – Neuroscientists at Trinity College in Dublin have discovered a fascinating connection between the retention of early life memories and brain developmental trajectories associated with autism. Most of us remember little of our experiences from before two years of age. This form of memory loss, termed “infantile amnesia” refers...
SAN DIEGO – Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced it has acquired global rights to ASP3652, a novel oral peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor from Astellas Pharma Inc. ASP3652 complements Autobahn’s brain-targeting chemistry platform, which uses FAAH-mediated...